Dual-mechanism inhalable nanocomposite restores the alveolar mucus barrier and enables deep-lesion delivery for synergistic treatment of pulmonary fibrosis.
Randomized trial shows improved barrier function and drug delivery in pulmonary fibrosis, suggesting enhanced therapeutic outcomes.
Key Points
This research aims to develop a dual-mechanism inhalable nanocomposite to restore the alveolar mucus barrier and deliver antifibrotic agents effectively for treating pulmonary fibrosis.
Developed an inhalable system combining calcium phosphate-coated celastrol liposomes with pirfenidone-loaded microgels.
Conducted both in vitro and in vivo studies to evaluate the efficacy of the CL-Shell/PF-µGel system.
Assessed pulmonary retention and fibroblast activation following administration of the nanocomposite.
The dual-mechanism system significantly enhanced pulmonary retention compared to conventional therapies.